Hims & Hers (NYSE:HIMS) gained 3.5% on Wednesday after the telehealth company unveiled its expansion into menopause and perimenopause treatment services, marking its latest move into the growing women’s health market.
The new service focuses on hormone-replacement therapies (HRT) and related care, tapping into what the company described as a major underserved segment — an estimated 1.3 million women in the U.S. enter menopause each year. reported that Hims & Hers sees this as a significant growth opportunity to further scale its digital health platform.
Dr. Jessica Shepherd, Chief Medical Officer of Hers — the company’s women’s health division — emphasized the lack of adequate menopause care nationwide. “Every woman will go through this. Does that mean they get the best care in how they navigate their symptoms? No,” she said, noting that only about 30% of OB/GYN residency programs currently offer formal training in menopause management.
The company expects the new offering to help Hers surpass $1 billion in annual revenue next year, building on strong momentum from other health categories including hair care, weight loss, and mental health. Hims & Hers generated $1.48 billion in total revenue last year and continues to expand its telehealth footprint through personalized, subscription-based treatment programs.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.